- Home
- MCR vs NBP Comparison
MCR vs NBP Comparison
Compare MCR & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCR | NBP |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 275.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MCR | NBP |
|---|---|---|
| Price | $5.98 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 71.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-07-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.81 |
| 52 Week High | $6.57 | $5.19 |
Technical Indicators
Market Signals| Indicator | MCR | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 19.77 |
| Support Level | $5.84 | N/A |
| Resistance Level | $6.10 | $2.73 |
| Average True Range (ATR) | 0.06 | 0.15 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 29.21 | 3.06 |
Price Performance
Historical ComparisonAbout MCR MFS Charter Income Trust
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.